background: Largehead Atractylodes Rhizome (LAR) is the most commonly used Chinese medicine to prevent early pregnancy loss due to threatened miscarriage. However, its safety profile during pregnancy is still not available. Here we aimed to identify the potential adverse effects of LAR on embryo-fetal development as well as prenatal and post-natal growth.
Introduction
Chinese medicines have been widely used to maintain good health and to prevent or treat various diseases for over 3000 years . Most Chinese medicines are derived from nature, including herbs, animal and mineral products (Chinese Pharmacopeia, 2010) . Chinese medicines have been commonly used in pregnancy (Westfall, 2001) , for reducing the chance of threatened miscarriage (Liang, 2008) and recurrent miscarriage (Shu et al., 2002) , for promoting recovery from abortions (Wang et al., 2006) and for stabilizing pregnancy (Sionneau, 1995) .
However, unexpected adverse effects of some Chinese medicines have been reported, such as nausea (Chen et al., 2001; Zhang, 2006) , dry mouth (Chen et al., 2001) , liver dysfunction (Su et al., 2006) , oral ulcer (Bai and Dong, 2010) , allergic reaction (Lin et al., 2010) , spontaneous abortion and preterm labor (Cui, 1998) , puerperal fever (Meng and Yang, 1988) and antepartum hemorrhage (Zhang, 2005) in pregnant women, and perinatal mortality, prematurity, congenital malformation, mental retardation and epilepsy in fetuses and newborns (Zhang, 2005) .
In our literature search, Largehead Atractylodes Rhizome (LAR) is the most commonly used Chinese medicine to prevent early pregnancy † Both authors contributed equally to this paper. loss due to threatened miscarriage . However, the reproductive toxicity of LAR in pregnancy is still unknown. In order to study the safety of LAR during pregnancy, various animals were used to screen maternal and perinatal toxicity of LAR in vivo.
Materials and Methods

LAR extract
Concentrated LAR extract was obtained from PuraPharm w Nongs, Hong Kong, with the accreditation of Good Manufacturing Practice certification for patient uses. LAR extracts were dissolved in phosphate-buffered saline solution. The test dosages for animals were calculated from the reference clinical dosages for humans according to the Food and Drug Administration (FDA)-recommended formula:
1/3 (You, 2007) . d A stands for the known dose for animal A (mg/kg) while d B stands for the unknown dose for animal B, and R A and R B are the body size factors, i.e. 59 for mouse, 90 for rat, 93 for rabbit and 100 for human (You, 2007) , while W A and W B are the weights of animal A and B. The median clinical dose of LAR for humans is 12 g/day, which is regarded as a single (1×) clinical dose for humans (Chinese Pharmacopeia, 2010) . The 1× clinical dose of LAR for mice was 1.18 g/kg, for rats it was 0.84 g/kg and for rabbits it was 0.64 g/kg. The LAR extracts were weighed, dissolved in distilled water to the test doses in hot water at 958C for 30 min and then cooled down to room temperature before administration. Various doses from 1× to double (2×), triple (3×) and up to six time (6×) clinical doses were tested in our study.
Animals
Pregnant Institute of Cancer Research (ICR) mice, Sprague -Dawley (SD) rats and New Zealand White (NZW) rabbits were obtained from the Laboratory Animal Services Centre in The Chinese University of Hong Kong. Virgin, sexually mature female and male animals were mated overnight, and female animals were examined for a copulation plug in vagina in the next morning. The day that vaginal plug was identified, was regarded as gestation Day 0 (E0). Guidelines were followed for the use and care of all laboratory animals as set in the university. Animals were housed in a room with temperature maintained at 258C, a 12/12 h light -dark cycle, with standard water and rodent chow ad libitum provided. Animal Ethics approvals (06/073/MIS, 09/073/MIS, 09/015/GRF) were obtained for the animal experimentations.
Experimental designs
We aimed to identify the potential reproductive toxicity of LAR during pregnancy, and to determine the specific gestational periods being affected. Maternal and perinatal adverse effects of LAR were tested by an in vivo test in pregnant animals, according to the guidelines of the FDA for toxicity studies on medicines or medical products (ICH-S5A, 1994) . It is recommended that pregnant animals during defined gestational stages and developmental windows and throughout the whole gestational and post-natal periods are screened. A combination of this 'most probable option' approach was used to examine for effects on early pregnancy, embryo-fetal development, and prenatal and post-natal growth. This leaves no gaps between the developmental stages and allows direct or indirect evaluation of all stages of the pregnancy process.
In mice, the experimental periods were divided into the implantation period (from E3 to E6, n ¼ 5 for each test dose), gastrulation period (E6 -E8, n ¼ 5 for each test dose), organogenesis period (E8 -E15, n ¼ 5 for each test dose), maturation period (E15 to delivery, n ¼ 5 for each test dose) and whole gestational period (E0 to delivery, n ¼ 5 for each test dose). In the maturation and whole gestational periods, all pups were followed until post-natal Day 28. Since LAR is clinically used in early and late pregnancy after implantation (Li, 2011) , the preimplantation period was not investigated in present study. Mice were administered daily with a single bolus at the desired dose, 1.18, 2.36 or 3.54 g/kg (1×, 2×, 3× clinical doses) for the study groups and vehicle (0× clinical dose) for the negative control group. Before administration, each animal was weighed. LAR extracts were administrated orally via a sterile gastric tubule. To avoid overload and regurgitation of the administered LAR extract, the final volume of LAR extract solution was adjusted to ,0.5 ml in total. Maternal, perinatal or post-natal outcomes were collected at the end of each experimental period. For the implantation, gastrulation and organogenesis periods, preimplantation loss was determined by subtracting the number of implantation sites from the total corpora lutea. Postimplantation loss was determined by early and late fetal resorption of the disintegrated and assimilated dead embryos in the uterus. Fetal size parameters including crown-rump length (CRL) and head length (HL) of the embryos were measured and the number of somites was counted under a dissecting microscope. Placental size was determined by the average of largest and perpendicular diameters of each placenta. For maturation and whole gestational periods, the duration of pregnancy was determined from the day of conception plug to the day of parturition. Prenatal and post-natal mortality were determined by stillbirth and death after birth, respectively. Major malformations including external and visceral structural anomalies were recorded at necropsy. Skeletal anomalies were further investigated by microCT, Alcian Blue-Alizarin Red skeleton staining and histological examinations. Neonatal weights were recorded daily after birth and average weight gains were calculated. Maternal weight gain and litter size were recorded in all periods.
In rats and rabbits, sensitive periods for developmental toxicity to teratogenic agents from E6 to E21 (n ¼ 3, for each test dose) and from E8 to E29 (n ¼ 3, for each test dose), respectively (Kaufman, 1997) , were tested. Higher and increasing doses from 3× and up to 6× clinical doses (2.48 and 4.96 g/kg for rats; 1.87 and 3.74 g/kg for rabbits) were daily administered to the animals until reproductive effects were identified. Vehicle (0× clinical dose) was included as negative control group for comparison. Maternal weight gain, litter size, CRL, fetal weight, placental weight and fetal limb parameters were measured. Adverse pregnancy outcomes including fetal resorptions and major external malformations were recorded.
Statistical analysis
Homogeneity of variance was tested by Bartlett's examination. Homogenous data were analyzed using parametric independent Student's T-test, while non-homogenous data were analyzed using non-parametric Mann-Whitney U test. Post-implantation loss, number of malformed fetuses, and prenatal and post-natal mortality were presented as percentages per litters. The incidence of the adverse effects was analyzed using x 2 test for all groups followed by Fisher's exact test with Bonferroni correction for each treatment group versus the negative control. Differences were considered to be significant at P , 0.05.
Results
Maternal reproductive toxicity in mice
No significant maternal weight gains were found in any clinical dose groups in the implantation, gastrulation, maturation and the whole gestational periods (P . 0.05). Maternal weight gain in the 3× clinical dose group only was significantly higher than in the control groups in organogenesis period (P , 0.05). The duration of pregnancy was significantly increased in the 2× clinical dose groups in whole gestational Continued period (P , 0.05). There were no significant differences in litter size in any experimental periods in any clinical dose groups (P . 0.05). Postimplantation loss rates were significantly higher in the 2× and 3× clinical dose groups in the implantation period (P , 0.001). Early fetal resorption rates in the gastrulation period increased with higher clinical doses, but were not significantly different from the control group (P . 0.05). The late fetal resorption rate was significantly higher only in the 1× clinical dose group in the organogenesis period (P , 0.05) ( Table I) .
Perinatal reproductive toxicity in mice
Significant shorter CRLs were found in all clinical dose groups in the gastrulation period (P , 0.001). Potential reproductive toxicity of LAR 1× and 2× clinical dose groups (P , 0.01) and a reduced number of somites in the 1× clinical dose group (P , 0.001) were also identified in the gastrulation period. Significantly increased CRL and HL (P , 0.05) and placenta diameters (P , 0.001) were found in the 1× clinical dose group in the organogenesis period (Table I) . Neonatal weight gains were lower in all clinical dose groups in the maturation period, with significantly decreased neonatal weight gains on post-natal Day 7 in the 3× clinical dose group (P , 0.05) and on post-natal Day 14 in the 1× and 3× clinical dose groups (P , 0.05). A significantly decreased weight gain on post-natal Day 7 was observed in the 1× and 3× clinical dose groups only in the whole gestational period (P , 0.05). Pre-and post-natal mortality increased in all clinical dose groups in the maturation period, with a significant increase in the 2× and 3× clinical dose groups (P , 0.05) and a significantly increased stillbirth and early death rates (before post-natal Day 7; P , 0.05). Significant increases in post-natal mortality were shown in the 1× and 2× clinical dose groups in the whole gestational period (P , 0.05) due to significantly increased early death (before post-natal Day 7; P , 0.05) and late death (after post-natal Day 7; P , 0.05). No significant differences in numbers of stillbirth were found in any of study groups over the whole gestational period (P . 0.05).
Congenital malformation in mice
Increased congenital malformations were found in 3× clinical dose groups over the whole gestational period, but were not significantly different from 0× clinical dose group. Only skeletal anomalies were identified in the study groups. No major birth defect in other organs was identified in autopsy. Skeletal anomalies were found in live pups from the 2× clinical dose groups in maturation periods and from the 3× clinical dose groups in the whole gestational periods, including extensions of the upper limb (Fig. 1A ) and lower limb (Fig. 1B) in the maturation period. Skeleton staining confirmed posterior shoulder joint dislocation in the extended right upper limb (Fig. 1C) and congenital hip dislocation in the abbersted lower limb, ankle dislocation and caudal regression (Fig. 1D) . Neonates with skeleton anomalies were subjected to computerized tomography (CT) scanning and Alcian Blue -Alizarin Red skeletal staining (Kessel et al., 1990) . Extended adduction of left upper limb of another pup in whole gestational period was identified ( Fig. 2A) . CT scanning detected shortening of radius and the absence of ulna and oligodactyly in the malformed left upper limb (Fig. 2B) . Skeleton staining demonstrated the losses of ulna and distal digits, and shortening of the humerus and radius in the malformed left upper limb (Fig. 2C) . Smaller bone, lower trabecular density and enlarged cartilage cells suggested a delay in endochondral ossification, cartilage formation and development in the elbow of the left upper limb ( Fig. 2D ; Table I ).
Reproductive toxicity in rats
No significant differences in maternal weight gain, litter size or fetal resorption were found between the study groups (3×, 6× clinical dose groups) and control group (P . 0.05). There were also no significant differences in CRL, HL, placental parameters, fetal weight or limb parameters in any of the study groups (P . 0.05). No congenital malformations or skeletal anomalies were identified in rats (Table II) . 
Reproductive toxicity in rabbits
No significance differences were found in litter size, CRL, fetal weight or placenta weight between the 0× and 3× clinical dose groups (P . 0.05). Fetal resorption and the incidences of hydrops fetalis and short ear fetus were identified (Fig. 3A and B) , and the incidences were higher in 3× clinical dose group, but were not significantly different from the control group (P . 0.05). No significance differences were found in fetal limb parameters, fetal hand parameters or fetal foot parameters. CT images demonstrated that the skeleton of hydrops fetalis was underdeveloped (Fig. 3C) . Shortening of limbs, absence of essential joint structures as well as dysostosis of parietal bone, occipital bone and mandible were identified in hydrops fetalis from the 3× clinical dose group. CT images shown that the short ear fetus had an incomplete mandibular bone, missing bones in ethmoid, absence of tympanic ring and larger fontanel with less developed parietal bone (Fig. 3D) . Since reproductive effects of LAR at the 3× clinical dose in rabbits were identified, higher clinical doses (i.e. 6× dose) were not investigated (Table III) .
Discussion
In this study, we tested the safety of LAR during pregnancy. High doses of LAR resulted in an increase in post-implantation loss, hindrances in fetal morphological development, decreases in neonatal weight gain, prolonged duration of pregnancy and higher post-natal mortality in mice. Moderate to severe congenital skeleton malformations caused by LAR were observed in both mice and rabbits but not in rats. Higher incidences of fetal resorption, hydrops fetalis and short ear fetus were identified in rabbits exposed to high dose of LAR. It is suggested that LAR has potential reproductive, developmental and skeletal toxicity in both mice and rabbits. No significant effect of LAR was observed in rats.
In mice, the effects on maternal weight change were not dosedependent. The lack of significance differences in study and control groups were due to smaller weight gain and larger variation in early gestation. There was a trend toward increased post-implantation loss with increasing LAR doses during implantation. A clear doseresponse relationship in the implantation period was observed. It suggested that LAR may prohibit embryo development after implantation. CRL, HL and number of somites, and morphological parameters were examined as estimates of embryonic development. A significant reduction in CRL was found in all study groups in the gastrulation period in an apparent dose-dependent pattern. The significant reductions in CRL, HL and number of somites suggested that LAR might hinder the development of the embryo in the gastrulation period. Gastrulation involves many rapid cell cycles and differentiations (Beddington and Robertson, 1998) , and LAR might have affected cell cycle activity and differentiation resulting in retardation of embryonic development. In the organogenesis period, the effects on CRL, HL and placenta length were not dose-dependent. This suggested that LAR might not have any developmental effects during the organogenesis period. There was a trend toward reduced neonatal weight gain with increasing LAR doses in maturation period. Post-natal mortality was significantly increased with higher dose of LAR, which indicated a clear dose-dependent effect. Reduced neonatal weight gain and increased post-natal mortality suggested that LAR might have developmental toxicity in mice during maturation and over the whole gestational period.
Skeletal anomalies were identified in higher clinical dose groups in both maturation and whole gestational periods. Neonates exhibited posterior shoulder joint dislocation in the right upper limb, congenital hip dislocation, ankle dislocation and caudal regression. Another pup presented with missing the ulna and distal digits, with shortening of the humerus and radius in the left upper limb. Delays in endochondral ossification and cartilage formation were identified. Bone starts to develop in E12.5 in mice, with the commitment of mesenchymal cells to osteogenic lineage and formation of cartilage core (Caplan and Pechak, 1987) . These results suggested that LAR might have toxicity that hindered the bone formation or development.
To further determine whether species sensitivity affects the results, different clinical doses of LAR were administered on rats and rabbits. SD rats, one of the most common laboratory animal used in toxicity studies, were found to be insensitive to LAR. This suggested that pregnant mice are more sensitive to administration of LAR than pregnant rats. Similar species differences were observed in a previous study (Jahnke et al., 2006) . Fetal resorptions, hydrops fetalis and short ear fetus occurred with higher incidences in LAR exposed groups in rabbits, suggested that LAR might have developmental toxicity in rabbits. The cases of hydrops fetalis in rabbits were similar to the fetal resorption in mice in the gastrulation and organogenesis periods, which suggested that LAR might induce post-implantation Fetal resorption (%) 0 ( Potential reproductive toxicity of LAR loss in mice and rabbits. The skeletons of hydrops fetalis and short ear fetus were underdeveloped and with various skeletal anomalies. Similar skeletal anomalies were observed in mice exposed to high doses of LAR. These further confirmed the developmental skeletal toxicity of LAR in mice and rabbits. Reproductive and developmental toxicity of LAR during pregnancy was identified. In traditional Chinese Medicine, LAR is commonly used in pregnancy for strengthening the conditions of 'Spleen' and 'Kidney', improving the blood circulation for relieving edema due to excessive damp caused by 'Spleen' deficiency (Sionneau, 1995) and preventing miscarriage (Liang, 2008) . LAR is also used to improve the immune system (Li et al., 2009) , to protect kidney from severe lupus nephritis (Tsai et al., 2011) , and to treat diabetic foot ulcer (Chan et al., 2007) , cerebral ischemia (Lin et al., 2008) , rectal radiation injuries (Tian and Wang, 2008) and various cancers (Liu et al., 2008; Guo et al., 2011) .
There are several limitations in our study. LAR is often used in formulae, to enhance the synergetic therapeutic effects of other herbal medicines. Formulae such as Shou Tai Pill are more often used for prevention of miscarriage and promotion of pregnancy (Ding, 1999; Zhou, 2006; Li, 2011) . The single herb, LAR, instead of a formulae was studied due to the increased complexity of using formulae in scientific research. Further studies should be carried out with the formulae used in pregnancy. On the other hand, sensitivities toward LAR in different animal species were studied; however, given the complexity of human-animal relations, differences in physiology, anatomy and metabolism between humans and animals make it difficult to predict human outcomes reliably (Hackam and Redelmeier, 2006) . Hence, different species sensitivities toward LAR should be taken into account when animal studies were designed. Nevertheless, the classifications of gestational periods into different experimental periods were according to the physiological changes and development process in animals. They may not represent the development stages in the human correspondingly. In our study periods, animals were daily administered with LAR throughout the whole experimental period; however, humans usually take Chinese medicines at different intervals during pregnancy.
The reproductive and developmental toxicity of LAR raised the concerns of clinical application of LAR during pregnancy. Chinese medicines are generally regarded by the public as effective, gentle and safe (Marcus and Snodgrass, 2005) . LAR increases the proliferation rate of lymphocytes, and is important in modulating immune-response induction (Lee et al., 2007) . Lymphocytes play an important role in embryo implantation and placental development during early pregnancy (Tian and Zhang, 1998) . It suggested that LAR might promote early pregnancy. LAR can also increase T-helper 2 cytokine interleukin 10 level, resulting in an anti-abortive effect (Zhong, 2008) . However, an imbalance between the level of T-helper 1 and T-helper 2 will lead to poor pregnancy outcomes . Additionally, LAR has the ability to inhibit lipid peroxidation (Qiu et al., 1996) . Significant increases in levels of lipid peroxidation have been found during normal pregnancy (Patil et al., 2006) ; thus it suggested that LAR might have an adverse effect on pregnancy. However, there has been no systematic scientific study on the safety of LAR during pregnancy, leading to a lack of information about the reproductive toxicity of LAR. Atractylenolide I and III are the two major phytochemical components of LAR. Unfortunately, no relevant pharmacological data and toxicological properties are available for pregnancy or embryo-fetal development. Further detailed studies of Atractylenolide I and III and other components should characterize the reproductive toxicity of LAR extracts as identified in the present study.
In conclusion, mice and rabbits were found to be sensitive to maternal exposure of LAR during pregnancy. Early LAR exposure significantly decreased fetal growth parameters and significantly increased the post-implantation loss in mice. Late LAR exposure significantly increased the duration of pregnancy, and prenatal and post-natal mortality in mice. Congenital skeletal malformations were recorded in higher clinical dose groups. Higher incidences of fetal resorptions, hydrops fetalis and short ear anomalies were observed in high clinical dose groups in rabbits. Although species variations were identified, maternal, perinatal and post-natal toxicity of LAR raises the concerns of clinical application of LAR during pregnancy. Potential reproductive toxicity of LAR in pregnant animals was identified within the clinical dose equivalent to that used by humans. Caution should be taken in clinical applications of LAR during pregnancy. Potential reproductive toxicity of LAR
